Welcome to the World of Investor Rights Law Are You Keeping Up with the Methode Electronics, Inc. Case? Hey there, fellow investors! Have you heard about the latest news involving Methode Electronics, Inc. (NYSE: MEI)? If not, let me fill you in on the details. The Rosen Law Firm, a renowned global investor rights law…

Amprius Technologies Receives Contracts for High-Performance Cells Clever, Personable, Unconventional, and Reader-Friendly Amprius Technologies, Inc. (“Amprius” or the “Company”) (NYSE: AMPX) has recently announced that it has secured two contracts to supply 40 Ah high-performance cells for Light Electric Vehicle (“LEV”) applications. The total value of these contracts exceeds $20 million, showcasing Amprius’ expertise in…

Exploring Ontario’s Mineral Resources with Neotech Metals Corp. Discovering the Green Transition, One Grant at a Time Hold onto your hockey sticks, maple syrup lovers! Neotech Metals Corp. is making waves in the exploration world with their recent approval by the Ontario Junior Exploration Program (OJEP). This exciting news means that Neotech will receive $200,000…

A Closer Look at the Class Action Lawsuit Against Agenus Inc. In a recent announcement, Pomerantz LLP revealed that a class action lawsuit has been filed against Agenus Inc. This legal action has been taken against the company and certain officers, and is set to unfold in the United States District Court for the District…

Teva Pharmaceuticals Announces Positive Results for SOLARIS Trial New Hope for Patients with Schizophrenia In a groundbreaking announcement, Teva Pharmaceuticals revealed new positive efficacy, safety, and tolerability results for the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial, evaluating TEV-‘749 in adult patients diagnosed with schizophrenia. The study showed that TEV-‘749 met the primary…

The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Arbor Realty Trust, Inc. LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Arbor Realty Trust, Inc. (“Arbor Realty” or “the Company”) (NYSE:ABR) for violations of…

Dupixent recommended for EU approval to treat eosinophilic esophagitis in children Positive Recommendation by CHMP Paris and Tarrytown, NY, September 20, 2024 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the expanded approval of Dupixent (dupilumab) in the European Union (EU) for the treatment…